Quality of Life in Metastatic Breast Cancer (MBC) Patients in Second Line Monochemotherapy
- Conditions
- First Posted Date
- 2015-03-31
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- Celgene
- Target Recruit Count
- 149
- Registration Number
- NCT02403869
- Locations
- 🇪🇸
Hospital Virgen de Valme, Sevilla, Andalucía, Spain
🇪🇸Hospital Juan Ramón Jiménez, Huelva, Andalucía, Spain
🇪🇸Hospital Universitario Son Espases, Palma Mallorca, Baleares, Spain
Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2015-03-27
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Celgene
- Target Recruit Count
- 85
- Registration Number
- NCT02400242
- Locations
- 🇺🇸
Gabrail Cancer Center Research, Canton, Ohio, United States
🇺🇸University of Miami Medical Center, Miami, Florida, United States
🇺🇸Local Institution - 104, Boston, Massachusetts, United States
Post-authorisation Study of Biological Relapse in Patients With Multiple Myeloma
- Conditions
- First Posted Date
- 2015-03-20
- Last Posted Date
- 2021-09-14
- Lead Sponsor
- Celgene
- Target Recruit Count
- 415
- Registration Number
- NCT02394210
- Locations
- 🇪🇸
Hospital Miguel Servet, Zaragoza, Aragón, Spain
🇪🇸Hospital Royo Villanova, Zaragoza, Aragón, Spain
🇪🇸Hospital Son Llatzer, Palma de Mallorca, Baleares, Spain
PK and Safety Study of AG-221 in Healthy Male Japanese Subjects and Healthy Male Caucasian Subjects
- First Posted Date
- 2015-03-13
- Last Posted Date
- 2018-10-30
- Lead Sponsor
- Celgene
- Target Recruit Count
- 62
- Registration Number
- NCT02387866
- Locations
- 🇺🇸
Parexel International, Glendale, California, United States
A Non-interventional,Observational Post Authorization Study of Patients With Multiple Myeloma Treated With Lenalidomide TR
- Conditions
- First Posted Date
- 2015-03-13
- Last Posted Date
- 2019-09-26
- Lead Sponsor
- Celgene
- Target Recruit Count
- 500
- Registration Number
- NCT02387879
- Locations
- 🇹🇷
Baskent University Adana Application and Research Hospital, Adana, Turkey
🇹🇷Cukurova University Medical Faculty, Adana, Turkey
🇹🇷Ankara University Medical Faculty, Ankara, Turkey
Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant
- First Posted Date
- 2015-02-27
- Last Posted Date
- 2018-12-14
- Lead Sponsor
- Celgene
- Target Recruit Count
- 97
- Registration Number
- NCT02374099
- Locations
- 🇺🇸
Florida Cancer Specialists, West Palm Beach, Florida, United States
🇧🇪Clinique Sainte Elisabeth - Service d'Oncologie, Namur, Belgium
🇩🇪Universitatsklinikum Hamburg-Eppendorf / IVDP, Hamburg, Germany
A Randomized, Double-blind, Study to Explore the Effect of GED-0301 in Subjects With Active Crohn's Disease
- First Posted Date
- 2015-02-20
- Last Posted Date
- 2019-01-10
- Lead Sponsor
- Celgene
- Target Recruit Count
- 64
- Registration Number
- NCT02367183
- Locations
- 🇺🇸
Shafran Gastroenterology Center, Winter Park, Florida, United States
🇺🇸University of Washington Medical Center, Seattle, Washington, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers
- First Posted Date
- 2015-02-20
- Last Posted Date
- 2021-08-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 60
- Registration Number
- NCT02367196
- Locations
- 🇪🇸
Duran i Reynals Institut Catala d'Oncologia, Barcelona, Spain
🇺🇸Scottsdale Healthcare Research Institute, Scottsdale, Arizona, United States
🇪🇸Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year
- First Posted Date
- 2015-01-28
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 65
- Registration Number
- NCT02348528
- Locations
- 🇨🇳
Xiangya Hospital of Central South University, Changsha, China
🇨🇳1st Hospital Zhejiang University (The First Affiliated Hospital of Zhejiang University ), Hangzhou, China
🇨🇳Shanghai Changzheng Hospital, Shanghai, China
A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2015-01-22
- Last Posted Date
- 2020-08-28
- Lead Sponsor
- Celgene
- Target Recruit Count
- 59
- Registration Number
- NCT02343536
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Weill Cornell Medicine, New York, New York, United States